Introduction
============

Lung cancer remains the leading cause of cancer death in both men and women worldwide \[[@b1-crt-2016-522]\], including in Korea \[[@b2-crt-2016-522]\]. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers, and 30% to 40% of these patients present with unresectable stage IIIA and IIIB disease \[[@b3-crt-2016-522]\]. For stage III NSCLC patients with a good performance status (PS), combined-modality therapy using chemotherapy and thoracic radiation therapy represents the standard of care. In addition, several phase III trials have demonstrated that the concurrent administration of these two modalities improves long-term survival relative to sequential strategies, resulting in the general acceptance of concurrent chemoradiotherapy (CCRT) as a vital component of standard therapeutic paradigms \[[@b4-crt-2016-522],[@b5-crt-2016-522]\]. Despite this improved survival, more than two thirds of patients develop overt metastatic disease within 2 to 3 years, and most patients die from their disease as a result of distant failure. Therefore, control of occult micrometastatic disease remains a challenge in this patient population.

However, molecularly-targeted therapy using epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) has brought new enthusiasm to the treatment of NSCLC patients over the last decade. While the initial clinical trials did not demonstrate a survival benefit with EGFR-TKIs for the overall population of advanced NSCLC patients \[[@b6-crt-2016-522]\], a specific subset of patients carrying mutations on the kinase domain of *EGFR* gene were found to be highly sensitive to the these drugs \[[@b7-crt-2016-522],[@b8-crt-2016-522]\]. Encouraged by these results, we thought that if cases were properly selected, unresectable stage III NSCLC patients would benefit from EGFR-TKI treatment as good as those with stage IV NSCLC. Thus, we designed a randomized phase II trial to evaluate the efficacy and toxicity of EGFR-TKI erlotinib incorporated into the CCRT setting for patients with *EGFR*-mutant stage III NSCLC.

This study was also designed to develop an optimal treatment strategy to resolve occult micrometastatic disease by administering more effective chemotherapy at full dose before or after CCRT for patients with *EGFR* unknown or wild-type tumors. Earlier randomized trials that reported inferior outcomes for induction chemotherapy followed by radiotherapy (RT) utilized old chemotherapeutic agents such as vinblastine, vindesine, and mitomycin \[[@b4-crt-2016-522],[@b5-crt-2016-522]\]. Therefore, we explored the impact of more effective irinotecan plus cisplatin (IP) regimen as induction or consolidation chemotherapy. We used the IP regimen because the clinical synergism of this combination was demonstrated in several clinical trials that reported 25%-59% response rates and 1-year survival rates as high as 57% for patients with advanced NSCLC \[[@b9-crt-2016-522]-[@b12-crt-2016-522]\]. We previously conducted a phase II study using IP regimen in patients with advanced NSCLC. Of 77 assessable patients, 36 achieved partial response (PR); thus, the overall response rate (ORR) was 47% \[[@b13-crt-2016-522]\]. In our study, the median overall survival (OS) was 15.2 months (range, 2.9 to 29.7 months) with a 1-year survival rate of 63.3% (95% confidence interval \[CI\], 52.4% to 74.1%). Furthermore, IP regimen showed a more favorable toxicity profile than etoposide plus cisplatin (EP) in a phase III trial of chemo-naïve extensive stage small cell lung cancer \[[@b14-crt-2016-522]\]. Based on the favorable activity and toxicity profile, we selected IP regimen rather than EP for the concurrent treatment.

Collectively, we conducted two parallel randomized phase II studies to incorporate erlotinib or IP into CCRT for stage III NSCLC stratified by the *EGFR* mutation status.

Materials and Methods
=====================

1. Eligibility
--------------

Patients (≥ 18 years of age) with a cytological or histological confirmation of NSCLC, unresectable stage IIIA (T1-3N2) confirmed by surgeon or stage-IIIB (T4N2 or T1-4N3 not malignant pleural effusion) according to the American Joint Committee on Cancer sixth edition, a PS of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale, and no prior therapy for NSCLC were eligible. Adequate tissue samples for *EGFR* mutation analysis were requested, but not mandatory. The qualifying laboratory criteria were as follows: absolute neutrophil counts of ≥ 2,000/μL, platelets of ≥ 100,000/μL, hemoglobin of ≥ 10 g/dL, total serum bilirubin of ≤ 1.0×the institutional upper limit of normal (ULN), serum transaminases of ≤ 2.0×ULN, and serum creatinine levels ≤ 1.0×ULN. Patients whose forced expiratory volumes in 1 second were lower than 1 L by spirometry were excluded. All the patients provided written informed consent, and this study was approved by the institutional review board (ClinicalTrials. gov, NCT00620269).

2. Study design and treatment
-----------------------------

This was a single center, open-label, parallel, randomized, phase II study. The stratification factors were supraclavicular lymph node, histology (adenocarcinoma vs. non-adenocarcinoma), and smoking history.

Patients with *EGFR*-mutant tumors initially received three cycles of erlotinib and were then treated by CCRT with either two cycles of erlotinib (arm A) or IP (arm B) ([Fig. 1](#f1-crt-2016-522){ref-type="fig"}). After completion of CCRT, the patients in arm A received consolidation therapy with six cycles of erlotinib, while those in arm B were observed until disease progression and restarted erlotinib after progression. Patients with *EGFR* unknown or wild-type tumors were treated by either induction therapy with three cycles of IP followed by CCRT with two cycles of IP (arm C) or CCRT with two cycles of IP followed by consolidation therapy with three cycles of IP (arm D). Erlotinib was administered at 150 mg daily with a 3-week cycle. IP was administered with cisplatin 30 mg/m^2^ (days 1 and 8) and irinotecan 60 mg/m^2^ (days 1 and 8) during RT or with cisplatin 30 mg/m^2^ (days 1 and 8) and irinotecan 65 mg/m^2^ (days 1 and 8) during induction or consolidation therapy with a 3-week cycle.

All thoracic RT was based on computed tomography (CT) planning. The CT simulation was performed with a GE LightSpeed RT (GE Healthcare, Milwaukee, WI) or Picker CT-Simulator UltraZ (Philips Medical System, Best, The Netherlands), and each scan slice had a thickness of 35 mm. The target volumes were defined as follows: gross tumor volume (GTV), primary tumor(s) and involved lymph node(s); clinical target volume (CTV), GTV+1 cm for microscopic tumor extension; planning target volume (PTV), CTV+5 mm margin. A minimum of 36 coplanar isocentric fields were designed for 3-dimensional conformal radiotherapy (3D-CRT) and intensity modulated radiotherapy (IMRT) with pinnacle radiotherapy treatment planning (RTP) systems (Philips Radiation Oncology Systems, Milpitas, CA) or the Eclipse RTP system, ver. 8.3 (Varian Medical System Inc., Palo Alto, CA). A once daily dose of 2.4 Gy was delivered up to 60 Gy in 25 fractions for 5 days per week. The daily dose of 2.4 Gy was composed of 1.8 Gy to PTV and a concomitant boost dose of 0.6 Gy to GTV, with a field border defined as GTV+1-1.5 cm for 3D-CRT and planning GTV as GTV+8-10 mm considering set-up error and internal motion for IMRT.

3. Patient evaluation
---------------------

A disease assessment by chest CT was conducted after three cycles of induction therapy, 4 weeks after completion of CCRT, and then every 8 weeks thereafter until disease progression. The ORR was determined by the number of patients with complete response and PR according to the Response Evaluation Criteria in Solid Tumor committee 1.0 \[[@b15-crt-2016-522]\]. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events ver. 3.0.

4. Statistical analysis
-----------------------

The primary endpoints are ORR, toxicities, and OS. The secondary endpoints are progression-free survival (PFS) and patterns of failure. The sample size calculation was as follows.

1) For patients with *EGFR*-mutant tumor
----------------------------------------

Assuming accrual of 50 patients over 2 years and 2 years of follow-up, this number of patients will provide a 73% power to detect a 7-month difference in median survival with a type I error of 0.05 based on a one-sided test (i.e., 17 months for the historical CCRT vs. 24 months for the *EGFR* mutation positive group as a whole). However, allowing for an invaluable rate of up to 10%, the total sample size will be 56 patients (per each arm of 28 patients).

2) For patients with *EGFR* unknown or wild-type tumor
------------------------------------------------------

Assuming accrual of 148 patients over 2 years and 2 years of follow-up from the last accrual, with 80% power to detect a 7-months difference in median survival with a type I error of 0.05 based on a one-sided test (i.e., 17 months for the historical CCRT vs. 24 months for the *EGFR* mutation negative group with new treatment as a whole), we need 74 patients per arm. However, allowing for a follow-up loss rate of up to 5%, the total sample size will be total 156 patients per each arm of 78 patients.

OS was calculated from the start date of study treatment to the date of death. PFS was calculated from the start date of study treatment to the first objective documentation date of progressive disease or death. Pearson's chi-square test or Fisher exact test was used to compare the ORR of treatment arms, where appropriate. Survival time was estimated using the Kaplan-Meier method, and survival difference between groups was assessed using the log-rank test.

5. *EGFR* mutation analysis
---------------------------

Nucleotide sequencing of the kinase domain of the *EGFR* gene (exons 19, 20, and 21) was conducted using nested polymerase chain reaction amplification of the individual exons. The details of the sequencing procedure have been described elsewhere \[[@b16-crt-2016-522]\]. When this study was initially designed, there was no information available regarding drug sensitivity for uncommon *EGFR* mutations; thus, patients having tumors with all types of *EGFR* mutation were allocated into arm A and B.

Results
=======

Recruitment started in March of 2008 and stopped in August of 2014 due to slow accrual rate. Overall, 73 patients were screened and 59 were enrolled. We analyzed *EGFR* mutations in tumor biopsy samples of 40 patients. There were 12 patients with *EGFR*-mutant tumors (exon 19 deletion in 10, exon 20 insertion in two) who were randomly assigned to arm A (n=7) and arm B (n=5), while 47 patients with 28 *EGFR*-wild and 19 *EGFR*-unknown tumors were assigned to arm C (n=22) and arm D (n=25) ([S1 Fig](#SD1-crt-2016-522){ref-type="supplementary-material"}.).

1. Patient characteristics
--------------------------

Patient characteristics are shown in [Table 1](#t1-crt-2016-522){ref-type="table"}. Age, ECOG PS, stage, and involvement of supraclavicular lymph node were well balanced among the four arms. About 70% had stage IIIB disease and about 40% had supraclavicular lymph node involvement. As expected, the proportion of female, never smoker, and patients with adenocarcinoma was higher in the *EGFR*-mutant groups (arm A and B), but lower in the *EGFR* wild-type or unknown groups (arm C and D). The patients with *EGFR*-unknown tumors were more likely to have squamous cell carcinoma histology than those with *EGFR* wild-type and mutant tumor (70.6% vs. 30.0% vs. 8.3%, p \< 0.001).

2. Efficacy
-----------

After induction therapy, the ORR was 71.4% in arm A, 80.0% in arm B, and 70.0% in arm C ([S2 Table](#SD2-crt-2016-522){ref-type="supplementary-material"}). The best ORR after CCRT was 71.4% in arm A, 80.0% in arm B, 70.0% in arm C, and 73.9% in arm D ([Table 2](#t2-crt-2016-522){ref-type="table"}). According to the *EGFR* mutation status, the best ORR after CCRT was 75.0% in the *EGFR*-mutant type group, 80.8% in the *EGFR*-wild type group, and 58.8% in the *EGFR*-unknown group ([S3 Table](#SD3-crt-2016-522){ref-type="supplementary-material"}). Of 12 patients with *EGFR*-mutant tumors, nine showed PR as the best ORR, but one patient (exon 20 insertion) did show stable disease and two patients (exon 19 deletion and exon 20 insertion) had progressive disease (PD).

Median follow-up duration of the 13 surviving patients was 23.6 months (range, 15.3 to 88.2). There was no difference in PFS among treatment arms, with a median PFS of 11.6 months (95% CI, 0.1 to 23.2) in arm A, 8.1 months (95% CI, 2.7 to 13.6) in arm B, 9.0 months (95% CI, 7.5 to 10.4) in arm C, and 12.3 months (95% CI, 6.6 to 18.0) in arm D (p=0.134) ([Fig. 2](#f2-crt-2016-522){ref-type="fig"}). In terms of OS, the median OS was 39.3 months (95% CI, 0.7 to 83.3) versus 31.2 months (95% CI, 0.1 to 90.2) for arm A vs. arm B (p=0.442) and 16.3 months (95% CI, 3.8 to 28.9) versus 25.3 months (95% CI, 20.8 to 29.8) for arm C vs. arm D (p=0.050) ([S4 Fig](#SD4-crt-2016-522){ref-type="supplementary-material"}.). There was a trend towards longer OS in the *EGFR*-mutant groups than the *EGFR* wild-type or unknown groups: median OS, 39.3 months (95% CI, 0.1 to 89.6) versus 22.1 months (95% CI, 16.0 to 28.1), respectively (p=0.081) ([S5 Fig](#SD5-crt-2016-522){ref-type="supplementary-material"}.). When OS was compared between sensitive *EGFR*-mutant and wild-type groups, the median OS remained longer in patients with sensitive *EGFR*-mutant tumor than those with *EGFR* wild-type tumor (74.8 months \[95% CI, 5.4 to 144.2\] vs. 25.3 months \[95% CI, 20.1 to 30.6\]), respectively (p=0.034).

Of 11 patients with *EGFR*-mutant tumors experiencing PD, 10 received subsequent treatment ([S6 Table](#SD6-crt-2016-522){ref-type="supplementary-material"}). Eight of these patients received EGFR-TKI, six as a second-line treatment and two as a third line treatment after intervening chemotherapy. The ORR after EGFR-TKI treatment was 75% and the median PFS was 8.4 months (95% CI, 2.0 to 14.8). The median survival after PD was significantly longer in the *EGFR*-mutant groups than the *EGFR* wild-type or unknown groups: 25.4 months (95% CI, 19.5 to 31.5) versus 9.8 months (95% CI, 4.9 to 14.6), respectively (p=0.017).

3. Toxicities
-------------

There was no treatment-related mortality among all patients and all treatment regimens were tolerable. [Table 3](#t3-crt-2016-522){ref-type="table"} lists the severe hematologic and non-hematologic toxicities during the induction phase and during or after the CCRT phase. Grade 3 or 4 neutropenia developed more frequently, but not febrile neutropenia in patients treated with IP relative to those treated with erlotinib. There was no difference in the incidence of grade 3 or 4 radiation pneumonitis between CCRT with erlotinib and CCRT with IP (arm A vs. arm B to D, 0.0% vs. 6.5%, p=0.227).

4. Pattern of treatment failure
-------------------------------

At the time of study analysis, 44 treatment failure sites (74.6%) were known ([S7 Table](#SD7-crt-2016-522){ref-type="supplementary-material"}). Of the 44 treatment failures, the rates of loco-regional failure and distant failure were 36.3% and 47.7%, respectively. Among distant failure sites, lung and brain were the two most common. There was no significant difference in loco-regional or distant failure rates among the four arms. In the *EGFR*-mutant groups, the locoregional and distant failure rates were 27.3% and 63.3%, respectively, while they were 39.4% and 42.4% in the *EGFR* wild-type or unknown groups (p=0.463). The brain was more common as the first relapse site in the *EGFR*-mutant groups compared with the *EGFR* wild-type or unknown groups, even though there was no statistical significant difference between groups (45.5% vs. 18.2%, p=0.070).

Discussion
==========

To the best of our knowledge, this was the first randomized phase II study to incorporate tailored chemotherapy regimens into the CCRT setting according to *EGFR* mutation status for unresectable stage III NSCLC patients. Although this study was closed early because of slow accrual, the results suggested that the combined-modality treatment based on molecular diagnostics was feasible for unresectable stage III NSCLC patients. In addition, concurrent administration of erlotinib or irinotecan plus cisplatin together with thoracic RT was safe and well tolerated without unexpected adverse events.

The results demonstrated that specific subsets such as female, never smoker, and patients with adenocarcinoma had a high likelihood of carrying an *EGFR* mutation in stage III lung cancer, which is consistent with stage IV lung cancer \[[@b17-crt-2016-522]\]. Patients with *EGFR*-mutant tumor showed similar ORR and median PFS, but longer median OS when compared to patients with *EGFR*-wild type tumor. The discordance between OS and PFS was caused by effective systemic therapy, namely EGFR-TKI, applied to patients with *EGFR*-mutant tumor when the disease progressed after CCRT. Actually, the post-progression survival was significantly longer in patients with *EGFR*-mutant tumor compared to the other patients (p=0.017). Of the 12 patients having *EGFR*-mutant tumor, 11 experienced PD and eight received EGFR-TKIs during the disease course after PD. Their ORR to subsequent EGFR-TKIs was 75% with a median PFS of 8.4 months, which was comparable to the clinical outcome of EGFR-TKIs in chemo-naive patients with stage IIIB/IV *EGFR*-mutant tumor \[[@b18-crt-2016-522]-[@b20-crt-2016-522]\]. In this study, erlotinib was only given during three cycles of induction therapy for arm B and 11 cycles for arm A (three cycles of induction therapy, two cycles during and six cycles after CCRT). Thus, these groups appear to have remained sensitive to EGFR-TKIs at the time of progression and reuse of EGFR-TKIs was confirmed to be beneficial.

Approximately half of the patients with *EGFR*-mutant tumors presented with brain metastasis as the first site of treatment failure. The brain failure rate of this *EGFR*-mutant group was higher than the 15%-30% rate reported for unselected locally advanced NSCLC patients receiving standard curative multimodality treatment in previous studies \[[@b21-crt-2016-522]-[@b24-crt-2016-522]\]. This finding indicates that incorporation of EGFR-TKIs resulted in much better control of extracranial disease and increased survival for patients with *EGFR*-mutant tumor. Additionally, a high intrinsic potential for brain metastasis of *EGFR*-mutant tumor or incomplete drug penetration of the brain--blood barrier of EGFR-TKIs may explain the high incidence of brain failure in this patient group. Taken together, patients with stage III *EGFR*-mutant NSCLC may represent a distinct clinical subset, which warrants careful consideration in CCRT trial design and outcome evaluation.

When this study was designed, there were concerns about the possibility of EGFR-TKIs aggravating the radiationinduced pneumonitis because severe drug-induced interstitial lung disease is the most concerning toxicity of EGFR-TKIs, with an incidence of about 1% \[[@b25-crt-2016-522]\]. In a Japanese clinical trial, 38 patients with stage III adenocarcinoma received 250 mg gefitinib daily with thoracic RT after induction therapy and one of 35 patients stopped CCRT due to grade 3 pneumonitis \[[@b26-crt-2016-522]\]. In another prospective study, 49 stage III NSCLC patients whose ethnicity was mainly white received erlotinib 150 mg daily for 6 days a week during thoracic RT, but only three of 46 patients showed severe pneumonitis (two with grade 3 and one with grade 4) \[[@b27-crt-2016-522]\]. Although the subject numbers were small, our study also suggested that erlotinib before or during thoracic RT does not increase the incidence and severity of pneumonitis and can be safely added to CCRT.

We also tried to develop a more effective treatment schedule to control occult micrometastasis by applying a new chemotherapy regimen at full dose before or after CCRT in patients with *EGFR* unknown or wild-type tumor. This study showed there was no difference in the toxicity profile between the two treatment arms, but the consolidation treatment arm (arm D) showed longer survival than the induction treatment arm (arm C), even though the sample size was too small to draw a firm conclusion. The survival outcome of the consolidation arm seems favorable, even when compared to those of historical randomized trials, which rarely exceeded 17 months after CCRT \[[@b4-crt-2016-522],[@b5-crt-2016-522]\]. These results were consistent with those of other previous randomized phase II studies \[[@b28-crt-2016-522]\], suggesting that upfront CCRT followed by chemotherapy may be superior to chemotherapy followed by CCRT when both treatment strategies can achieve high completion rate. However, these results need to be confirmed in large randomized studies.

Among patients with unresectable stage III NSCLC, those carrying *EGFR*-mutant tumors might show a distinct clinical course with longer survival in contrast to other subsets. Thus, it is necessary to allocate appropriate treatment regimens to stage III NSCLC patients based on molecular characteristics in the era of molecular-targeted therapy. This randomized phase II study demonstrated that this treatment approach is feasible and well tolerated in this population.

Erlotinib and irinotecan were provided by Roche Korea and Pfizer, Inc., respectively.

The study was supported in part by Roche Korea Co., Ltd. and a National Cancer Center Research grant (1410540).
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###### 

Patient characteristics

  Characteristic                                             *EGFR* mutant type (n=12)   *EGFR* wild type (n=28) or unknown (n=19)                
  ---------------------------------------------------------- --------------------------- ------------------------------------------- ------------ ------------
  **Age, median (range, yr)**                                61 (37-78)                  62 (51-78)                                  60 (37-74)   61 (42-76)
  **Sex**                                                                                                                                         
   Female                                                    5 (71.4)                    3 (60.0)                                    3 (13.6)     4 (16.0)
   Male                                                      2 (28.6)                    2 (40.0)                                    19 (86.4)    21 (84.0)
  **Smoking**                                                                                                                                     
   Never                                                     5 (71.4)                    3 (60.0)                                    2 (9.1)      3 (12.0)
   Ever                                                      2 (28.6)                    2 (40.0)                                    20 (90.9)    22 (88.0)
  **ECOG PS**                                                                                                                                     
   0                                                         3 (42.9)                    1 (20.0)                                    10 (45.5)    7 (28.0)
   1                                                         4 (57.1)                    4 (80.0)                                    12 (54.5)    18 (72.0)
  **Pathology**                                                                                                                                   
   ADC                                                       6 (85.7)                    5 (100)                                     8 (36.4)     9 (36.0)
   Non-ADC                                                   1 (14.3)                    0                                           14 (63.6)    16 (64.0)
  **Stage^[a)](#tfn1-crt-2016-522){ref-type="table-fn"}^**                                                                                        
   IIIA                                                      2 (28.6)                    1 (20.0)                                    5 (22.7)     7 (28.0)
   IIIB                                                      5 (71.4)                    4 (80.0)                                    17 (77.3)    18 (72.0)
  **Supraclavicular LN**                                                                                                                          
   Involved                                                  2 (28.6)                    2 (40.0)                                    12 (54.5)    11 (44.0)
   Not involved                                              5 (71.4)                    3 (60.0)                                    10 (45.5)    14 (56.0)

Values are presented as number (%). EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group; PS, performance status; ADC, adenocarcinoma; LN, lymph node.

Staging according to the seventh edition of American Joint Committee on Cancer TNM staging system.

###### 

ORR after concurrent chemoradiotherapy

  Response             Arm A (n=7)   Arm B (n=5)   Arm C (n=22)   Arm D (n=25)   p-value
  -------------------- ------------- ------------- -------------- -------------- ---------
  CR                   0             0             0              1              
  PR                   5             4             14             16             
  SD                   0             1             5              6              
  PD                   2             0             1              0              
  NE                   0             0             2              2              
  ORR (CR+PR), n (%)   5/7 (71.4)    4/5 (80.0)    14/20 (70.0)   17/23 (73.9)   0.906

CR, complete response; PR, partial response; SD, stable disease; PD, disease progression; NE, not evaluable; ORR, overall response rate.

###### 

Severe adverse effects

  Adverse effect          During induction therapy ≥ grade 3 (%)   During and after chemoradiotherapy ≥ grade 3 (%)                              
  ----------------------- ---------------------------------------- -------------------------------------------------- ------ ----- ------ ------ ------
  Anemia                  0.0                                      0.0                                                13.6   0.0   0.0    22.2   4.2
  Neutropenia             0.0                                      0.0                                                50.0   0.0   20.0   72.2   41.7
  Febrile neutropenia     0.0                                      0.0                                                0.0    0.0   0.0    0.0    4.2
  Thrombocytopenia        0.0                                      0.0                                                4.5    0.0   0.0    11.1   4.2
  AST/ALT increased       0.0                                      0.0                                                0.0    0.0   0.0    0.0    0.0
  Creatinine increased    0.0                                      0.0                                                4.5    0.0   0.0    0.0    0.0
  Fatigue/Asthenia        0.0                                      0.0                                                0.0    0.0   20.0   0.0    12.5
  Anorexia                0.0                                      0.0                                                0.0    0.0   20.0   0.0    4.2
  Nausea                  0.0                                      0.0                                                0.0    0.0   0.0    0.0    4.2
  Vomiting                0.0                                      0.0                                                0.0    0.0   0.0    0.0    0.0
  Skin rash               14.3                                     20.0                                               0.0    0.0   0.0    0.0    0.0
  Diarrhea                0.0                                      0.0                                                4.5    0.0   0.0    5.6    0.0
  Oral mucositis          0.0                                      0.0                                                0.0    0.0   0.0    0.0    0.0
  Radiation esophagitis   \-                                       \-                                                 \-     0.0   20.0   0.0    4.2
  Radiation pneumonitis   \-                                       \-                                                 \-     0.0   0.0    5.6    8.7

AST, aspartate aminotransferase; ALT, alanine transaminase.
